Launch of QUVIVIQ™ by Nxera Pharma and Shionogi in Japan
Nxera Pharma and Shionogi Introduce QUVIVIQ™ in Japan
Tokyo, Japan and Cambridge, UK – Nxera Pharma Co., Ltd. (TSE: 4565), previously known as Sosei Group, in partnership with Shionogi & Co., Ltd., has officially launched QUVIVIQ™ (daridorexant) in Japan. This innovative treatment provides a new option for adults grappling with insomnia.
What is QUVIVIQ™?
QUVIVIQ™ is an oral medication categorized as a Dual Orexin Receptor Antagonist (DORA). It effectively binds to the orexin receptors in the brain that are responsible for wakefulness, thus helping ease the transition into sleep. By inhibiting excessive wake signals, it aids those who have trouble falling asleep or staying asleep.
Partnership Responsibilities
Nxera Pharma Japan Co., Ltd., a subsidiary of Nxera Pharma, has obtained the necessary approvals and will oversee certain aspects of the drug product's provision. Meanwhile, Shionogi will handle all distribution and sales activities of QUVIVIQ™ in Japan, stemming from a strategic partnership that strengthens both companies' positions in the market.
A Commitment to Patient Care
This milestone underscores Nxera's dedication to developing pioneering therapeutics aimed at enhancing patient outcomes in Japan. The collaboration with Shionogi aligns with Shionogi's initiative to focus on the Quality of Life (QOL) disease area, ensuring that QUVIVIQ™ will contribute positively to the treatment landscape for insomnia.
Significance of Insomnia Treatment
Insomnia is a widespread condition marked by difficulty in initiating or maintaining sleep, significantly impeding daily functioning and well-being. Statistics indicate that approximately 20% of Japanese adults face challenges in achieving restful sleep, leading to negative implications for their health—both mentally and physically.
Understanding Insomnia
Insomnia disorders are defined by a consistent pattern of insufficient sleep, impacting various aspects of life and well-being. It differs from occasional poor sleep, as it manifests regularly, resulting in notable distress and daily impairments. With effective treatments, the goal is to improve not only the quality and quantity of sleep but also daytime performance.
Treatment Approaches
Current treatment strategies for insomnia range from behavioral therapies to pharmacological options, and they are tailored to individual patient needs. Solutions such as cognitive behavioral therapy, sleep hygiene education, and, when appropriate, medications like QUVIVIQ™ form a comprehensive approach to managing insomnia effectively.
About Shionogi
Shionogi is dedicated to delivering optimal healthcare solutions while fostering a society conducive to longer, healthier lives. Their commitment to addressing unmet medical needs is evident in their focus on therapeutic areas that significantly benefit patients.
About Nxera Pharma
Nxera Pharma (previously Sosei Heptares) is at the forefront of biopharmaceutical innovation, aiming to address healthcare challenges on a global scale. With a robust pipeline of over 30 active programs, Nxera collaborates with prominent pharmaceutical companies to develop advanced therapies addressing major health needs.
Contact Information
Nxera Media and Investor Relations
Kentaro Tahara (VP Investor Relations)
Shinichiro Nishishita (VP Investor Relations)
Maya Bennison (Communications Manager)
Contact: +81 (0)3 5210 3399 | +44 (0)1223 949390 | Email: IR@Nxera.life
Frequently Asked Questions
What is QUVIVIQ™?
QUVIVIQ™ is a dual orexin receptor antagonist designed to help adults with insomnia by promoting better sleep.
Who developed QUVIVIQ™?
QUVIVIQ™ was developed by Nxera Pharma in partnership with Shionogi, building on research by Idorsia Pharmaceuticals Ltd.
How does QUVIVIQ™ work?
It works by blocking orexin receptors in the brain, reducing wakefulness and facilitating sleep onset.
What are the dosage recommendations for QUVIVIQ™?
The standard dose is 50 mg taken orally before bed, with an option of a lower 25 mg dose depending on individual needs.
How prevalent is insomnia in Japan?
Estimates indicate that around 20% of Japanese adults experience insomnia, impacting their overall health and daily functioning.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.